Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Abstract In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in an...

Full description

Bibliographic Details
Published in:	Blood Cancer Journal
Main Authors:	Laahn Foster, Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-10-01
Online Access:	https://doi.org/10.1038/s41408-025-01355-0

Similar Items

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
by: Ajai Chari, et al.
Published: (2024-07-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN
by: C. Rodriguez, et al.
Published: (2022-06-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
by: Natalie S. Callander, et al.
Published: (2024-04-01)

EVALUATION OF DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (D-VRD) INDUCTION FOLLOWED BY DARATUMUMAB AND LENALIDOMIDE (DR) MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN BRAZIL
by: JTD Souto-Filho, et al.
Published: (2024-10-01)

Nerón, auriga solar
by: Jose Ignacio San Vicente González de Aspuru
Published: (2018-11-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Sebastian Grosicki, et al.
Published: (2023-08-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
by: K. Weisel, et al.
Published: (2023-05-01)

Ultraviolet Flux Variation of Epsilon Aurigae
by: Young Woon Kang
Published: (1990-06-01)

UBV Monitoring of EPS Aurigae (I)
by: Il-Seong Nha, et al.
Published: (1988-06-01)

First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report
by: E. Amabile, et al.
Published: (2024-01-01)

Monocyte or white blood cell counts and β microglobulin predict the durable efficacy of daratumumab with lenalidomide
by: Yutaka Shimazu, et al.
Published: (2022-12-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
by: MA Dimopoulos, et al.
Published: (2022-04-01)

An Eccentric Planet Orbiting the Polar V808 Aurigae
by: McKenna Leichty, et al.
Published: (2024-01-01)

Extreme Long Period Eclipsing Binary Epsilon Aurigae
by: Mun-Suk Chun, et al.
Published: (1990-06-01)

Photoelectric Observations of Epsilon Aurigae from 1982 to 1985
by: Young-Soo Kim
Published: (1989-12-01)

C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL
by: E. Antonioli, et al.
Published: (2025-09-01)

Investigation on Planck scale physics by the AURIGA gravitational bar detector
by: Francesco Marin, et al.
Published: (2014-01-01)

FOUR NEW VARIABLE STARS NEAR CL AURIGAE. II
by: Chun-Hwey Kim, et al.
Published: (2010-11-01)

Successful Daratumumab, Lenalidomide, and Dexamethasone Treatment of Refractory Type I Cryoglobulinemia From Monoclonal Gammopathy of Undetermined Significance
by: Karen J. Shou, et al.
Published: (2024-11-01)

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation
by: Rebecca W. Silbermann, et al.
Published: (2023-08-01)

Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report
by: Pierre-Yves Sansen, et al.
Published: (2024-01-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Period Analysis for the F Component of the ɛ Aurigae System Using Wavelets
by: Hyouk Kim
Published: (2008-03-01)

Atmospheric Eclipsing Binary Zeta Aurigae in the 1987-1988 Eclipse (II)
by: Il-Seong Nha
Published: (1991-12-01)

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA
by: L. Cani, et al.
Published: (2025-09-01)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
by: Wenjiao Tang, et al.
Published: (2024-01-01)

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
by: Inger S. Nijhof, et al.
Published: (2015-02-01)

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
by: Michael. S. van der Veer, et al.
Published: (2011-02-01)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
by: Benjamin A. Derman, et al.
Published: (2024-05-01)

VLT/MUSE Detection of the AB Aurigae b Protoplanet with Hα Spectroscopy
by: Thayne Currie, et al.
Published: (2025-01-01)

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
by: H. Einsele, et al.
Published: (2023-05-01)

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
by: Matthew Lee, et al.
Published: (2022-01-01)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)

C003 | MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
by: F. Gay, et al.
Published: (2025-09-01)

The complete mitochondrial genome of threadfin butterflyfish, Chaetodon auriga (Chaetodontiformes: Chaetodontidae) and phylogenetic analysis
by: Maheshkumar Prakash Patil, et al.
Published: (2022-11-01)